SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
bluebird bio, Inc. (BLUE) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+175.5%).
- 分析师共识目标价 $13.69 (+175.5% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 38/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
0/100
Debt-to-Equity & liquidity
→ Health
估值概览 — BLUE
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.57
EV/EBITDA0.0
每股数据
EPS (TTM)$-24.84
每股账面价值$0.00
每股营收$8.65
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$13.69 (+175.5%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$-4.81 |
$14.08M |
$-166.78M |
-1184.6% |
| 2016 |
$-7.07 |
$6.16M |
$-263.51M |
-4281.2% |
| 2017 |
$-7.71 |
$35.43M |
$-335.64M |
-947.4% |
| 2018 |
$-10.68 |
$54.58M |
$-555.63M |
-1018% |
| 2019 |
$-14.31 |
$44.67M |
$-789.61M |
-1767.5% |
| 2020 |
$-9.95 |
$250.73M |
$-618.7M |
-246.8% |
| 2021 |
$-8.16 |
$3.66M |
$-562.64M |
-15364.2% |
| 2022 |
$-3.39 |
$3.6M |
$-266.58M |
-7411.1% |
| 2023 |
$-1.93 |
$29.5M |
$-211.91M |
-718.4% |
| 2024 |
$-24.84 |
$83.81M |
$-240.72M |
-287.2% |
